Active-ingredient Dossier
Everolimus
Active-ingredient Dossier for Everolimus (mammalian target of rapamycin inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled…
- Brand: AFINITOR
- Brand: EVEROCAN
- Brand: CERTICAN
- Brand: EVEROLIMUS-TEVA
- Brand: TEVA-EVEROLIMUS
- Therapeutic area: Oncology
- Therapeutic area: Immunology
What is
Everolimus Everolimus is a mammalian target of rapamycin inhibitor.
Australian brands containing
Everolimus — AFINITOR — EVEROCAN — CERTICAN — EVEROLIMUS-TEVA — TEVA-EVEROLIMUS
Therapeutic areas
Everolimus is registered in oncology (3 brands) and immunology (2 brands).
Sponsor landscape
Everolimus is marketed by four sponsors: Novartis Pharmaceuticals, Pharmacor, Teva Pharma, and Medis Pharma.
PBS and regulatory activity
Two brands containing everolimus have PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was on 1 July 2018, and the latest AusPAR was on 13 January 2017.